The products are likely to be manufactured at Amerigen’s SFDA and US FDA approved finished dose plant in Suzhou, China, on receiving approval.
The marketing and sales of the products will be undertaken either by a Chinese affiliate of VIWA or a third party.
Amerigen president and CEO John Lowry said the joint venture represents the first initiative by Amerigen to bring quality and locally manufactured branded generic products to the Chinese market there by establishing an Amerigen brand in China.
"We anticipate that additional collaborations will be established to further this strategy," Lowry added.